Open AccessA Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients
Author(s) -
Aaron J. Ahearn,
Thin Thin Maw,
R. K. Mehta,
Juliet Emamaullee,
Jim Kim,
Emily Blodget,
Jeffrey Kahn,
Linda Sher,
Yuri Genyk
Publication year - 2021
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003953
Subject(s) - medicine , covid-19 , kidney transplantation , retrospective cohort study , kidney , gastroenterology , disease , infectious disease (medical specialty)
(COVID-19) has resulted in significant morbidity and mortality in solid organ transplant recipients. In December 2020, at the peak of the Los Angeles outbreak, our center rapidly implemented a protocol to improve outpatient management and provide bamlanivimab or casirivimab-imdevimab [COVID monoclonal antibody (mAb) therapies] to all eligible COVID-19 positive liver and kidney transplant recipients.